Sakagami K, Takeuchi H, Matsumoto T, Tsuboi K, Ohsaki H, Tanaka K, Ohiwa K, Orita K
Jpn J Surg. 1986 Sep;16(5):318-22. doi: 10.1007/BF02470553.
In order to clarify the beneficial effect of donor-specific blood transfusions (DST) on kidney allograft survival, sera from 16 patients treated with DST were studied using the mixed lymphocyte culture (MLC) serum inhibition test. The results demonstrate that MLC inhibitory factors could be induced in the serum of the recipients after the completion of DST, and that these factors are directed against cells of the recipient but not against cell from the donor. Regarding the correlation with rejection episodes and clinical outcome, a significant improvement in renal transplant survival and reduction in rejection episodes was observed when MLC inhibitory factors were present in post-DST sera. These data suggest that such factors may contain antibodies directed against recognition sites on T lymphocytes, e.g., anti-idiotypic antibodies, and be associated with prolonged graft survival of living-related, high MLC-reactive one-haplotype-mismatched kidney.
为阐明供者特异性输血(DST)对肾移植存活的有益作用,运用混合淋巴细胞培养(MLC)血清抑制试验对16例接受DST治疗患者的血清进行了研究。结果表明,在完成DST后,受者血清中可诱导出MLC抑制因子,且这些因子针对受者细胞而非供者细胞。关于与排斥反应发作及临床结局的相关性,当DST后血清中存在MLC抑制因子时,观察到肾移植存活率显著提高且排斥反应发作减少。这些数据提示,此类因子可能含有针对T淋巴细胞识别位点的抗体,如抗独特型抗体,并与亲属活体、高MLC反应性单倍型错配肾移植的长期存活相关。